Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

May 4, 2022

NASDAQ US Health Care Biotechnology earnings 74 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, and thank you for being with us on today's call. Robert Blum, our President and Chief Executive Officer, will start things off with a quick look at the quarter and what's happened recently. Fady Malik, EVP of R&D, will share updates on omecamtiv mecarbil and aficamten. Andrew Callos, EVP and Chief Commercial Officer, will talk about commercialization planning work for omecamtiv mecarbil along with our franchise strategy for aficamten. Stuart Kupfer, SVP and Chief Medical Officer, will give an update on reldesemtiv. Robert Wong, VP and Chief Accounting Officer, will walk through the financials for the quarter just ended; and Ching Jaw, SVP and Chief Financial Officer, will cover our financial outlook and corporate development strategies. Last, Robert Blum will offer closing remarks and go over expected key milestones for 2022. Please be aware that parts of what we discuss next, including our answers to questions, include statements tied to future events and performance instead of historical facts, and these are forward-looking statements. What actually happens may differ materially from what these forward-looking statements project. More details about factors that could make our actual results differ materially from those in these forward-looking statements can be found in our SEC filings, including our current report on our first quarter 2022 financial results filed today on Form 8-K. We take on no obligation to update any forward-looking statements after this call; and with that, I'll hand the call over to Robert.

Robert Blum

executive
#2

Thanks, Diane, and I appreciate all of you once more for being on today's call. Our first quarter was a productive one, and we're getting nearer to the transformation we've planned — becoming a completely integrated company spanning research, development and commercial activity. The standout item: FDA accepted our NDA for omecamtiv mecarbil for filing, with a PDUFA date of November 20 — pardon me, November 30, 2022. From that point on, we've been in continuous dialogue with FDA regarding particular questions, and Cytokinetics' team has worked hard to get timely answers back to them. Shortly we'll sit down with FDA for the customary mid-cycle review of our application. So far, most questions have been administrative in nature or have backed up extra analyses they asked for. Acceptance of the NDA also stood as a major derisking step that unlocked certain spending tied to our carefully paced commercial readiness work; we've kept growing our teams and constructing a commercial operation to back a possible near-term approval of omecamtiv mecarbil, plus possible commercialization of aficamten once our pivotal trials wrap up — SEQUOIA-HCM — and then its possible submission to FDA for approval. It's a pleasure to draw very high-caliber talent, and the people we're bringing aboard carry terrific experience and expertise. On the clinical side, at ACC we presented further data from 2 fresh analyses out of GALACTIC-HF, which deepen our grasp of both the clinical and pharmacoeconomic effects tied to adding omecamtiv mecarbil treatment on top of standard-of-care therapy. Our belief holds that when given alongside standard of care, and for the appropriate patient, omecamtiv mecarbil can deliver a meaningful impact on important outcomes. That clinical opportunity, we believe, provides a strong business rationale for building commercial capabilities and for serving the objectives of our cardiac muscle franchise. Extending that idea, we achieved notable progress during the quarter in the aficamten development program, among it launching enrollment for SEQUOIA-HCM, the pivotal Phase III trial of aficamten in symptomatic obstructive HCM patients. As Fady will detail, site start-up and activation work is moving at the expected pace, as are patient screening and enrollment. After the positive Cohort 3 results from REDWOOD-HCM that we shared during the quarter, we're now enrolling into SEQUOIA-HCM patients whose background therapy includes disopyramide — a key milestone and a chance to include the sickest patients who need new therapeutic options. Enrollment has also begun in Cohort 4 of REDWOOD-HCM, for nonobstructive HCM patients, a significant segment representing roughly 1/3 of the prevalent HCM population. As the first quarter closed, our financial position stayed strong, with projected cash runway exceeding 2 years, even though we anticipate operating expenses might rise next year. The coming 12 months are going to mark a real turning point for us, with significant milestones spanning our pipeline, and we're getting nearer to delivering on the commitment we made to patients dealing with conditions where muscle function is impaired — bringing them new medicines that work by targeting muscle. So with that said, I'll hand things over now to Fady, please.

Fady Malik

executive
#3

Appreciate that, Robert. As the FDA reviews the NDA, we're still gathering further insights from GALACTIC-HF. At ACC last month, we shared fresh findings from a GALACTIC-HF analysis demonstrating that the impact of omecamtiv mecarbil compared with placebo on the primary outcome looked comparable between patients who were hospitalized and those treated as outpatients, which suggests omecamtiv mecarbil lowers the primary outcome risk to a similar degree whether it's begun in the hospital or in the outpatient setting. On top of that, this analysis revealed that initiating omecamtiv mecarbil in the hospital proved both safe and well tolerated, which speaks to our ability to start omecamtiv mecarbil in these patients facing higher risk of rehospitalization and cardiovascular death. Notably, recently published studies indicate that medication begun while patients are hospitalized is tied to some of the strongest long-term adherence, which makes these findings even more meaningful. Also at ACC, we shared the complete results from METEORIC-HF, which assessed how 20 weeks of omecamtiv mecarbil treatment, versus placebo, affected exercise capacity. No effect appeared on the primary endpoint, a change in peak oxygen uptake, or peak VO2, measured through cardiopulmonary exercise testing from baseline through week 20. This trial sits alongside other heart failure therapy studies that demonstrated a positive cardiovascular outcome impact yet failed to affect exercise performance among heart failure patients. Such data further hints that affecting exercise capacity in this population may be especially difficult, perhaps because of comorbidities or deconditioning tied to heart failure. Findings from METEORIC do strengthen the safety profile of omecamtiv mecarbil, demonstrating that during peak exercise conditions, adverse events, major cardiac adverse events included, were comparable across the treatment arms. As we've said before, we don't anticipate that METEORIC-HF results will affect the NDA the FDA is currently reviewing; also, while ACC was underway, ACC, AHA and HFSA issued new joint guidelines, with updates on treatment options for patients who have heart failure with reduced ejection fraction. Specifically, the guidelines described the traits of patients whose persistent or worsening heart failure puts them at high risk for adverse cardiovascular outcomes. In addition, SGLT2 inhibitors became a fourth medication class in guideline-directed medical therapy, or GDMT. We think these updates bode well for possibly adding omecamtiv mecarbil to guidelines down the road as an add-on to standard-of-care therapy, especially for patients whose persistent or worsening heart failure keeps them symptomatic with elevated risks even while on GDMT. We keep getting ready for a possible omecamtiv mecarbil approval. On the medical affairs front, we doubled our therapeutic medical scientist team's size, brought on a field director and started recruiting for our managed health care medical sciences team. I also want to share some good news: 2 abstracts related to GALACTIC-HF have been accepted for the late-breaking science session at the European Society of Cardiology Heart Failure 2022, which will be held in Madrid between May 21 and May 24. The first abstract examines how omecamtiv mecarbil affects patients who have lower blood pressure, while the second looks at patients who had tricuspid regurgitation at baseline. We're eager to reconnect with our European colleagues, whom we haven't met with in quite a while because of the pandemic. Now, on to aficamten. As Robert said, this quarter proved productive for our wide-ranging development effort. In particular, we began enrolling patients in SEQUOIA-HCM, the pivotal Phase III study of aficamten for people with symptomatic obstructive HCM. SEQUOIA-HCM is going to evaluate whether aficamten can boost exercise capacity, symptoms and functional class among obstructive HCM patients, and it will use a personalized dosing approach to get the most out of the potential treatment effect and help patients hit their target dose fast. Given the favorable findings from Cohort 3 of REDWOOD-HCM, we are now enrolling patients whose background therapy contains disopyramide. U.S. sites are busy screening and enrolling patients, while numerous other sites are working through start-up steps. We anticipate that sites beyond the U.S. will start screening patients in early Q3. Also, this quarter we began enrollment in Cohort 4 of REDWOOD-HCM, which targets symptomatic patients who have nonobstructive HCM. In Cohort 4, 30 to 40 patients will be enrolled in an open-label design and given escalating doses of aficamten — 5, 10 or 15 milligrams — guided by echocardiography. Although safety and tolerability of aficamten make up the main objective, we are also assessing how aficamten influences left ventricular ejection fraction, New York Heart Association Functional Class and cardiac biomarkers, such as NT-proBNP; once Cohort 4 wraps up, we expect its data to shape the design and execution of a possible pivotal Phase III clinical trial in nonobstructive HCM. As a reminder, we said last quarter that we intend to launch a second Phase III clinical trial of aficamten in obstructive HCM during the second half of this year. Since so many of you have asked about this planned trial, allow me to clarify a few points. To start, the FDA did not ask for this trial, and we still consider SEQUOIA-HCM to be the only pivotal Phase III trial that would support our submission seeking approval of aficamten. Second, this extra Phase III trial is meant to give us a clearer picture of how aficamten should be positioned relative to standard-of-care therapy. Because of that, it won't be a head-to-head comparison with mavacamten. We think there's a chance to push the field forward with a next-in-class drug candidate by chasing key scientific questions; and this trial, together with others we might run, could answer questions that matter for grasping how a therapy with a novel mechanism of action should be used across patients with a range of disease severity and background therapy. Frequently, such studies wait until a drug has initial approval, yet our confidence in aficamten leads us to think starting them earlier is beneficial. There is, we recognize, heightened curiosity about how this trial is designed, and additional specifics are set to be shared by us later in the current year. In pursuit of our aim to disclose longer-term findings regarding aficamten treatment in obstructive HCM patients, we are delighted to report that the initial data cut from the open-label extension of REDWOOD-HCM is going to be showcased during a late-breaking science session at the Heart Failure 2022 meeting in Madrid; this interim analysis is set to encompass results from as many as 6 months of aficamten treatment. Aficamten treatment is ongoing for patients within the open-label extension, and additional examinations of this data are anticipated before the year ends. Turning our attention past aficamten, it is gratifying to note that the FDA has just approved mavacamten for treating obstructive HCM patients, which makes it the inaugural medical therapy for HCM to secure FDA approval. Congratulations are due from us to the teams whose efforts brought this novel therapeutic mechanism to patients, and we feel pride in this landmark moment, reflecting our role in the program's discovery; for HCM patients who have urgently required new treatments to ease the significant symptom burden they bear, this marks a pivotal event; we further hold the view that this landmark approval will supply background for the potential distinctiveness of our own aficamten once our pivotal trial results arrive. Having said that, I will now pass the call to Andrew for an update regarding our commercial writing efforts and the cardiovascular franchise strategy we have planned.

Andrew Callos

executive
#4

Appreciate that, Fady. Through Q1, we kept expanding our commercial organization and its capabilities; we started bringing on the leaders for our first-line sales team in the field, and we also filled important roles in marketing, market access, sales, and commercial operations; we've chosen a partner for patient support services, kept up payer discussions, and carried out activities that support putting our field force in place. As our engagement with payers goes on, we remain aware of how crucially important the possible value proposition for omecamtiv mecarbil is. Not long ago at ACC, we shared findings from an analysis of health care resource utilization drawn from GALACTIC-HF, demonstrating that within a subgroup of patients given omecamtiv mecarbil, resource intensity went down as measured by total days spent in the hospital. The projected possible cost offset came to $3,085, or 19%, for each patient, and 99% of those cost reductions stemmed from heart failure hospitalization among the patients who received omecamtiv mecarbil. Naturally, these data carry limitations, since how relevant they are depends on each payer. Still, when we think about the cut in payment hospitals confronted for 30-day readmissions among Medicare patients, plus the reality that heart failure prevalence keeps rising, this possible decrease in hospitalizations along with the related cost highlights the kinds of potential economic value propositions for omecamtiv mecarbil that we'll keep evaluating to guide our strategies. In addition, this quarter we put our signature on a master supply agreement covering drug supply, kicked off a number of significant digital system initiatives, among them enterprise resource planning and serialization, and brought on people for key supply chain leadership positions. We likewise finished a risk assessment covering our end-to-end supply chain and moved forward with suitable mitigation steps. As we've mentioned, our expanding cardiovascular commercial infrastructure, which backs the launch of omecamtiv mecarbil, will be put to use for the possible future commercialization of aficamten. Given growing market awareness of HCM and of how clinically useful cardiac myosin inhibitors are, we feel confident about the chance we have for the potential future launch of our next-in-class therapy. Thanks to the key properties that could affect how easy titration is, reversibility, and the capacity to hit target concentrations quickly, we're eager to draw on our commercial organization and the synergies that exist within the treatment community; and with that, I'll hand the call to Stuart for an update on reldesemtiv.

Stuart Kupfer

executive
#5

Andrew, thank you. During Q1, we kept on enrolling patients into COURAGE-ALS, the Phase III study of reldesemtiv for ALS. Recruitment has been going nicely, with more than 70 sites up and running across the U.S., Canada, Australia and Europe, and over 150 patients signed up. Carrying out rigorous, disciplined clinical research sits at the heart of our ethos and is vital to our mission. We're glad to have enrolled the largest number of ALS patients in recent clinical trials of any company, even prior to COURAGE-ALS, which is set to enroll 555 patients. The trial's primary endpoint is a change from baseline to 24 weeks in ALSFRS-R, an endpoint considered clinically relevant under both FDA and EMA guidances for evaluating a treatment effect on function in daily activities in ALS. A combined assessment of function and survival serves as the main secondary endpoint — a joint rank test of ALSFRS-R total score, time to onset of respiratory insufficiency and survival time up to 24 weeks. Additional secondary endpoints cover change from baseline to 24 weeks for vital capacity, the patient reported outcome questionnaire, LSAT 40 and bilateral handgrip strength. Showing our focus on patient centricity, we built COURAGE-ALS with meaningful input from patients and caregivers so as to optimize the patient experience and lighten their burden, including many remote visits. Also, so that patients can stay on background medicines, those currently on stable doses of riluzole and/or edaravone may enroll, and randomization is stratified accordingly; we likewise intend to give continued access to reldesemtiv for patients finishing COURAGE-ALS through an open-label extension trial. Beyond that, patients in COURAGE-ALS and those who took part in our earlier ALS trial will be able to join a managed access program created with the aim of ensuring safe, ethical and equitable access to reldesemtiv; through face-to-face meetings with investigators and patient advocates, we've gotten enthusiastic backing for the patient-friendly protocol in COURAGE-ALS. It rests on the solid foundation of our large and robust Phase II trial, FORTITUDE-ALS. Later this year, we anticipate the data monitoring committee will carry out the first interim analysis in the COURAGE-ALS trial, which will assess for futility and is triggered 12 weeks after roughly 1/3 of the planned number of patients is randomized. A second interim analysis will also assess for futility, and there will be an option for a fixed increase in total enrollment, if necessary, to augment statistical power of the trial. ALS is a devastating disease, and nobody understands that better than patients and their caregivers. They are desperate for new options and therapies. Our mission is to bring forward a new therapeutic option through high-integrity research and diligent investigation. And with that, I'll turn it over to Robert Wong.

Robert Wong

executive
#6

Appreciate that, Stuart. We closed out the first quarter holding roughly $686 million in cash and investments. During Q1 2022, our revenue stream consisted of funding from Astellas supporting COURAGE-ALS. Research and development costs for the first quarter of 2022 rose to $45.9 million, compared with $31.6 million during the same period in 2021. That jump was driven mainly by greater spending on our cardiac myosin inhibitor program, a new headquarter facility, and our skeletal muscle program. As anticipated, over 55% of R&D expenses went toward our cardiovascular programs, reflecting the work underway for the cardiac myosin inhibitor program, while our skeletal and early research activities accounted for the rest. General and administrative expenses for Q1 2022 totaled $33.1 million, climbing from $15.6 million in Q1 2021, because of increased commercial readiness spending along with higher personnel-related costs, stock-based compensation included. At this point, Ching will walk through our financial outlook and corporate development strategies.

Ching Jaw

executive
#7

Appreciate that, Robert. When the quarter closed, we held roughly $686 million in cash, and that figure includes the $200 million we got from Ji Xing and Royalty Pharma tied to the deals we announced in December of last year and January of this year, respectively. There's room for our balance sheet to get even stronger thanks to our arrangement with Royalty Pharma, which gives us access to long-term capital totaling as much as another $300 million, contingent on certain conditions, mainly to back the possible commercialization of omecamtiv mecarbil along with continued development of aficamten. We intend to stay disciplined in how we build out a commercial infrastructure, with spending linked to key derisking milestones. Because our plan is to bring on our sales force only following a possible NDA approval for omecamtiv mecarbil, we anticipate a slower ramp in commercial spending during 2022. Should omecamtiv mecarbil win approval in late 2022, we'd anticipate notably larger increases in spending tied to post-approval activity in 2023. Our corporate development approach stays centered on partnering plus longer-term strategies of sensibly building our organization. Through the quarter, we kept up business development conversations aimed at possible partnerships across Asia and Europe. To start, we're looking for a possible partner to help facilitate the launch of omecamtiv mecarbil in Europe. Since we're concentrating on our own U.S. launch, having a partner to commercialize omecamtiv mecarbil in Europe might provide an on-ramp for us to build our own capabilities there, so that we can support future commercialization of aficamten on our own; in Japan, we're aiming to partner omecamtiv mecarbil and aficamten together with a partner commercializing both potential medicines, much like how we partnered both with Ji Xing and in China. We've got a track record of strong dealmaking and look forward to keeping up these conversations with potential partners, with the goal of closing one or more deals this year. With that, I'll hand the call back to Robert Blum.

Robert Blum

executive
#8

Thanks, Ching. So, as you heard, we kicked off 2022 with significant advancement in our late-stage pipeline, plus strong expansion throughout the company to back the possible approval of omecamtiv mecarbil later in the year. We just crossed 300 employees, and I'm happy with the quality of talent and the know-how we're assembling company-wide. Given our leadership position in muscle biology and the potential of our medicines, candidates are eager to come aboard. I'd like to use this moment to express gratitude to our staff for everything they're doing to create the next outstanding biopharmaceutical firm. We just ran a thorough employee survey and saw 98% engagement, which highlights how deeply dedicated our people are to meaningful work for patients. In the quarter, we kept up intense efforts toward our objective of moving earlier-stage drug candidates forward, such as CK-136, our cardiac troponin activator, along with other muscle-directed compounds, into IND-enabling studies. Our cardiovascular pipeline keeps growing with novel mechanism drug candidates that draw on more than 2 decades of our trailblazing leadership in muscle biology and pharmacology, and there's more to share on those programs shortly. On the leadership side, we recently shared news about changes to our Board of Directors. Dr. Pat Gage, our Chairman of the Board since 2010, has retired from the Board. This was a planned transition that was announced more than a year ago. His retirement was a personal choice, and he leaves with our deepest respect and admiration; we're grateful for his many years of service to our Board. With Pat's retirement, Dr. John Henderson was appointed the new Chairman of the Board. John has been a member of our Board since 2009, and we're confident he'll lead with discipline and a strong vision for the company in his new role as Chairman. In addition, we named Dr. Bob Harrington to our Board. Bob's appointment comes after Rob Califf resigned from our Board, which happened because he was named FDA Commissioner. Like Rob, Bob is a cardiologist. Bob also serves as Chair of Medicine at Stanford and has a distinguished academic career, bringing broad experience from having overseen dozens of global cardiovascular clinical trials. We're delighted to welcome Bob to our Board. Lastly, as Ching explained, our recent and second deal with Royalty Pharma doesn't just extend our partnership — it also expands it, and it gives us ample runway to carry out our commercial and clinical plans in a prudent yet purposeful manner. As we keep executing against our Vision 2025, our capacity to monetize our pipeline so we can achieve our ambitious goals remains mission critical. This newer deal aligns with our corporate development strategies to affordably enable our transformation into a commercial-stage company while also continuing to speed up our development plans. Now I'll recap our key milestones for 2022. For omecamtiv mecarbil, we expect to launch omecamtiv mecarbil in the U.S., pending potential FDA approval in Q4 2022. Regarding aficamten, our plan is to keep adding obstructive HCM patients into SEQUOIA-HCM all through 2022. Enrollment should also continue for nonobstructive HCM patients in Cohort 4 of REDWOOD-HCM, and during this year's second half we anticipate launching a second Phase III study of aficamten in obstructive HCM. Also, as Fady mentioned, later this month at the Heart Failure 2022 meetings on May 23, 2022, we anticipate sharing results from REDWOOD-HCM OLE, the open-label extension trial of aficamten. With CK-136, we intend to restart that development program during this year; with reldesemtiv, our expectation is that the data monitoring committee will perform the first interim analysis from COURAGE-ALS in this year's second half. Turning to our continuing research, we look forward to pushing forward new muscle-directed compounds and running IND-enabling studies for 1 to 2 possible drug candidates. Operator, that being said, please let's open the call for questions now.

Carter Gould

analyst
#9

Great. Perhaps as a way to kick things off — for Robert and Fady, this is likely a good moment to have you both weigh in a bit on the mavacamten label and its pricing, and particularly on what that means for differentiation and the market opportunity. Robert, I realize you've never really given explicit guidance on pricing assumptions, but it does look directionally higher than what we and a lot of the Street had anticipated. I'd love to hear your thinking on those topics.

Robert Blum

executive
#10

Sure. I'll begin, and maybe hand it over to Fady. And we should also have Andrew weigh in, especially since your question touches on pricing. First, we want to congratulate BMS and all the colleagues at MyoKardia on this approval, and also the HCM patients, the clinical investigators, the efficacy groups, and everyone else who took part. That also includes Cytokinetics scientists who came up with the therapeutic hypothesis for cardiac myosin inhibition and who were part of the discovery of mavacamten; this is a significant milestone given that it's the first drug approved with an indication of obstructive HCM, and the data from EXPLORER are certainly compelling. That said, as others have noted, the label is now out in the public domain, and there are aspects of that label that we believe make sense and aspects of that label that create a next-in-class opportunity to potentially show differences. That's why we're running SEQUOIA-HCM, and we hope SEQUOIA-HCM will shed light on what could be next-in-class properties deliberately engineered into aficamten long ago. You asked about pricing. And yes, I think the pricing did land higher than most consensus, and we were part of that consensus expecting a different price. But even so, I think pricing is now arriving at something more comparable to surgical interventions. When you factor in how many echoes have to be done both to reach a steady-state target dose and also for a maintenance program for mavacamten, the costs run even higher. And we would expect BMS knows what they're doing, they've done their payer research; they've done their work around the pharmacoeconomics; and despite what ICER came in with, I expect BMS understands where the market-clearing price will be. And at the same time, I expect that from the standpoint of patient assistance and contracting, there are going to be programs, and we'll elaborate on how that could still lead to lesser net cost to patients and also help with reimbursement. So I think this is all still going to play out alongside what I'm sure will be sensible commercial launch plans that BMS is already putting in place; so with that, maybe I'll ask Fady or Andrew if there's anything more they want to elaborate on.

Fady Malik

executive
#11

Okay, I might take a moment to say a bit more about aficamten — the way we’ve worked on it, and what we believe it could offer when it comes to things like patient convenience, safety, and similar considerations. You can make your own comparisons, really. I’d add that with aficamten, under the SEQUOIA design, the dose escalation ought to finish in 6 to 8 weeks. We’re not expecting any dose interruptions. If EF is under 50, provided it stays above 40, there would only be downward dose titrations. So ideally, the results from SEQUOIA, along with those from the continuing open-label extension, would back a straightforward escalation approach that gets done in 6 to 8 weeks. Aficamten was created so that drug-drug interactions would be avoided. And so far, we have not found any meaningful drug-drug interactions involving aficamten. We have demonstrated that the effect is reversible in the data we’ve shared from REDWOOD, which I believe makes its titratability possible and also gives a way to raise or lower the dose safely. Those are the points I’d emphasize. That, and I think along with how SEQUOIA is being run, we’re looking at it both as monotherapy with other drugs such as beta blockers and calcium channel blockers, and as dual therapy using those agents, or with disopyramide plus beta blockers as background treatment. So I think we’ll end up with a pretty solid grasp of how it does across those different situations.

Robert Blum

executive
#12

Robert, do you have anything to add?

Andrew Callos

executive
#13

Sure, and I'll keep this brief, focusing on pricing. I won't go into detail about BMS' approach—clearly, as Robert mentioned, it may have landed a bit above what we anticipated. It's going to be worth watching how payers, meaning the market, respond. If they impose additional controls, such as prior authorization tied to the label or step therapy involving beta blockers or calcium channel blockers, we'll just have to see how those play out. The pricing came in flat, which means each dose carries an identical price, and that matches what we had expected. There may also be added expenses related to support programs and some leeway for negotiation. So I believe those are the elements that probably factored in, but we still have time. We'll keep assessing the market and determine where we land regarding labeling as we set our pricing going forward.

Roy Buchanan

analyst
#14

This is Roy, filling in for Jason. To begin, I have a few questions seeking clarification. Fady's remarks regarding the second obstructive HCM Phase III trial, which is set to begin in the second half, left me puzzled. According to him, it won't be a head-to-head comparison with mavacamten, but rather against a drug featuring a novel mechanism. Could you shed some light on that? I assume this is an approved drug, right?

Robert Blum

executive
#15

What he said wasn't quite that, though perhaps he can provide more detail.

Roy Buchanan

analyst
#16

All right.

Fady Malik

executive
#17

Roy, my wording was that this would serve as a standard-of-care therapy. That's why I didn't go into detail about how the second trial is designed. What I said was simply that mavacamten wouldn't be the comparator. It might instead be compared with standard of care, or with other elements of the disease.

Roy Buchanan

analyst
#18

Understood. That clears things up. OK then. When you talk about locking down the trial design, is that the only thing standing between you and getting that study underway?

Fady Malik

executive
#19

I sure wish launching studies happened that simply, but after the design is locked down, you've still got operational items to handle — IRB submissions, regulatory submissions, that kind of thing. And in the end we'll likely need a regulatory interaction too. So a handful of steps remain before enrollment can begin, though we have every one of them well in hand.

Roy Buchanan

analyst
#20

All right, that makes sense. Next, regarding COURAGE-ALS, you brought up expanding the number of participants. Is that something we can do at each of the interim points? And also, if the results turn out to be remarkably strong, is there a possibility of halting the study ahead of schedule because of how well it's working?

Stuart Kupfer

executive
#21

Stuart Kupfer here. I appreciate the question. The initial interim look serves solely to assess futility. Upsizing isn't permitted at that point, though it becomes available at the second interim analysis. As for ending early due to effectiveness, that second interim analysis covers a considerably wider scope—it encompasses futility as well as a possible halt for superiority, yet the threshold for that is extremely demanding. So we aren't really relying on that happening.

Joe Pantginis

analyst
#22

I'd like to stay on the topic of COURAGE as well. The enrollment you're seeing is quite encouraging, yet it's also somewhat troubling, since the indication underneath suggests demand is still elevated. So I wanted to zero in on the interims too, and perhaps on the whole picture. Are you able to share, or could you remind us, what the alpha spend amounts to for every one of the interim analyses, and for the overall study, what hurdle applies?

Stuart Kupfer

executive
#23

Correct. Those specifics haven't actually been made public by us. What I believe we can state is that when it comes to this initial interim analysis for futility, clearing it isn't really a demanding threshold for keeping the trial going. As a result, we have confidence that we will move beyond that interim analysis.

Robert Blum

executive
#24

What we've mentioned is that for us to hit the futility cutoff at the initial interim analysis, the arm receiving reldesemtiv would need to perform below the standard of care. And as Stuart notes, that is once again a threshold set quite low given what we already understand. Early stopping because of futility is permitted at the second interim. If not, it permits us to expand the size should we wish to amplify a signal that was observed, though that would remain blinded to us. The data monitoring committee would make that determination; therefore, in response to your question, we have not revealed any of the alpha spend.

Fady Malik

executive
#25

Let me clarify something about futility: no alpha is ever spent there. Nothing gets taken from alpha when you run any futility analysis. That only applies on the efficacy side, should you choose to build it in.

Joe Pantginis

analyst
#26

Understood. Understood. Then regarding omecamtiv, the first portion of my question is — and Robert, as you mentioned, at present it is largely administrative correspondence with the FDA. At this moment, would you view any of that correspondence as rate limiting? And second, on omecamtiv, I wanted to zero in on the METEORIC data specifically. Is there anything learned there that would permit the possibility of, let's say, adjusting the population or the protocol? Or has that possible route now been foreclosed?

Robert Blum

executive
#27

I will handle the first one and perhaps have Fady address the second. As for what you asked about the correspondence, the interactions with FDA, no, none of them do I view as rate-limiting or as having an impact on the time line for review and approval. Such interactions, in my view, are customary for an application of the type we submitted. And so, I think we are still on the same time line.

Fady Malik

executive
#28

On the second question about METEORIC — I don't believe we've actually pinpointed any subgroup among the METEORIC population where we could say with confidence that a substantial treatment effect exists, one big enough to justify running that trial again as such. That being said, the patients we enrolled in METEORIC were not very sick. In fact, they were pretty much the reverse of the population we enrolled in GALACTIC. So you could ask whether, if a trial were run in a substantially sicker group of patients, an improvement in exercise capacity might be observed. My sense is that remains an unanswered question, though I think it's unlikely we'll go after it. There are numerous operational difficulties with something along those lines.

Akash Tewari

analyst
#29

Amy here, filling in for Akash. Just two things. First, when we look at Mava's label, the advantage from Mava appeared reduced among patients taking a background beta blocker versus those who weren't. What's your explanation for this kind of phenomenon? Could it be that patients already on beta blockers at baseline might start with lower LBS, which could possibly constrain Mava's capacity to updose? And where might — where do you believe Afi could potentially set itself apart? Also, what does this phenomenon mean for physicians regarding concomitant use?

Robert Blum

executive
#30

Great questions. These are a few of the observations that emerged when these data were presented and published. Perhaps I'll ask Fady whether he'd like to weigh in on that.

Fady Malik

executive
#31

I'd like to speak broadly about how difficult it is to use beta blockers alongside exercise performance testing. In METEORIC, close to 90% of patients were taking beta blockers. These agents produce 2 distinct consequences, correct? They restrict how much a person's heart rate can rise, which matters for boosting cardiac output, and they additionally influence skeletal muscle, reducing its capacity to perform exercise. Therefore, within hypertrophic cardiomyopathy, mavacamten showed better exercise capacity among individuals on beta blockers, though those benefits were diminished, which is unsurprising given how those 2 treatments interact. The key issue, I believe, is whether beta-blocker treatment is truly necessary in HCM when a cardiac myosin inhibitor is being used. And in the end, should physicians be starting that therapy for the people they treat? Could they, by eventually swapping a beta blocker for a myosin inhibitor, achieve the greatest possible therapeutic gain and quality of life? As you might expect, these are significant research questions. And I believe that will develop — and the solution will develop over time.

Analyst

analyst
#32

Thanks, that's really useful. Now, on a separate note, mava appeared to deliver a bigger advantage for NYHA Class III individuals in EXPLORER. How do you expect aficamten might stack up against mava when treating severe cases?

Fady Malik

executive
#33

Once more, a head-to-head study isn't something we're running. So comparing precise figures across two trials is going to be quite difficult, since the patient groups won't be identical. Broadly speaking, though, I'd say those who are sicker tend to see larger gains. Their symptom burden is heavier, their exercise burden is heavier. There's simply more potential, so to speak, for improvement. That being the case, it isn't shocking, so to speak, that patients with more severe disease experience a bigger treatment effect < > with aficamten.

Salim Syed

analyst
#34

Just two items for me. First, regarding mavacamten — Robert, I'm curious to hear your view, since there's now a price established on the market for mavacamten, if I do a bit of quick arithmetic. Looking at consensus peak, mavacamten has topped out at roughly $3.5 billion at present. As for aficamten, from what I can gather, it's nearer to $1.5 billion or so. That adds up to roughly $5 billion. Those figures are global; but with a price now existing in the market, simply applying that $90,000 price point. And the figure shown in your slides was 190,000 symptomatic obstructive patients in the U.S. alone, clearly the TAMs you arrive at are considerably bigger, even under a 40% gross-to-net and 80% compliance assumption; so I'm just wondering, how do you view TAM given that a price now exists in the marketplace, and how might TAM develop over time for this specific disease?

Robert Blum

executive
#35

If what you're asking is whether there seem to be discrepancies between those underlying assumptions and the consensus estimates, my answer is yes. And I believe you've already highlighted that in some of your notes. I believe that with a price now set by BMS, it presents a chance for analysts and investors alike, as well as for those of us at Cytokinetics, to think through how we view this market opportunity; and we will do so, but consistent with data; and patients are still being enrolled by us in SEQUOIA; so it's really too early for me to elaborate much on what I mean by that. Eventually, I think this will all become clear. And our belief remains that a next-in-class opportunity has the potential to become the category leader.

Salim Syed

analyst
#36

Could this become a worldwide market worth more than $10 billion, in your view?

Robert Blum

executive
#37

That's not something I'll address. Still, my belief is that the direction this market eventually takes stands to gain from category expansion — people who right now go undiagnosed and untreated will get diagnosed and treated. And in the end, hopefully this mechanism of action carries over past obstructive HCM into nonobstructive disease, which includes some patient segments dealing with HFpEF. So in the end, I believe there's a chance — a quite substantial chance — for this to turn into a large business.

Salim Syed

analyst
#38

All right. Then a fast follow-up regarding the REMS, and what your base case looks like for Cytokinetics and aficamten. I realize it's early and Phase III data isn't in hand yet. Still, given the profile you've observed for aficamten in REDWOOD, the shallow PK/PD, the shorter half-life, and the mechanistic rationale for why toxic ejection fraction levels would be less likely — what's your base case on REM? Do you believe there's a chance that no REMS would be needed?

Robert Blum

executive
#39

Yeah. Once more, I won't offer a comparative claim; however, when we consider aficamten as an independent drug development program, and given the safety data already observed in REDWOOD-HCM, a REMS wouldn't necessarily be anticipated, though certain things must be demonstrated in SEQUOIA-HCM for us to ensure that. So we're moving into SEQUOIA-HCM aiming to elaborate on what the next-in-class properties might be, as could be affording a safety profile that potentially wouldn't require a REMS.

Fady Malik

executive
#40

Salim, one more thing I believe we should keep in mind: assuming we do reach the market when we hope to, this will by then no longer count as a novel drug class, and doctors are going to have greater familiarity with how a cardiac myosin inhibitor gets used. Clearly, there would be distinctions among the various drugs, along with a need to educate people about those distinctions. Still, this isn't a first-in-class arrival; therefore, that too could reduce the requirement for REM.

Madhu Kumar

analyst
#41

This is Amari calling in for Madhu. We've got a few questions. To start, at Heart Failure 2022 in May, for REDWOOD-OLE, what data can we anticipate regarding end points and the average follow-up duration? Then please walk us through how echo monitoring is handled in REDWOOD-OLE as well as SEQUOIA-HCM, and in what ways that matches or differs from earlier and current studies involving other myosin inhibitors and OECM. There's another question from me after that.

Robert Blum

executive
#42

Absolutely. Clearly, we don't intend to say anything that could put the data presentation at risk by going into detail about what to anticipate; however, this is a trial that now allows observation of a more durable effect. Our aim is to show that with aficamten, it's possible to get effects that keep going. So you'll see data on the use of aficamten as is — as Fady explained, through 6 months. I'll hand it to Fady now in case he has anything further to add.

Fady Malik

executive
#43

Yeah. I mean, I believe what you should anticipate are the types of items we've shown previously, which relate to gradients and EF and safety, NYHA class, that sort of thing; so I think what you'll observe is the — as an initial presentation, we'll likely concentrate on the items that — the same topics we've detailed in earlier presentations. Your second question concerned echo monitoring; and what I'll say is that the overall approach across every one of our trials is identical. Patients arrive on at least a 2-week cadence for an echo and the possibility of being titrated up to the following dose. In the OLE at this moment, we're limited to doses of 5, 10, 15 milligrams. In SEQUOIA, the maximum dose is 20 milligrams, so 5, 10, 15 and 20. And OLE is only limited due to the requirement to amend the protocol so the higher dose is permitted, which we're currently in the middle of doing. So those are the — so the dosing is fairly comparable across all the trials we're conducting.

Stuart Kupfer

executive
#44

I want to mention one more dataset that we're going to be gathering in OLE, and SEQUOIA involves cardiac MR—cardiac MRI information—looking at the heart's structure, how it functions, and fibrosis. This gives us a chance to look at reverse remodeling.

Fady Malik

executive
#45

But it will be premature to see that at this upcoming congress; so...

Analyst

analyst
#46

Excellent. Now for my second question — considering how this class has performed historically, which groups of patients with HCM would respond best to a myosin inhibitor?

Robert Blum

executive
#47

Which patient populations would stand to gain the most from a myosin inhibitor?

Analyst

analyst
#48

< > regarding NHCM.

Fady Malik

executive
#49

You mean NHCM? Is that — NHCM. Right. I was attempting to work out what you meant. So, a handful of criteria characterize someone with HCM, I'd say. The first, clearly, is how thick their ventricle is. The second involves biomarkers signaling a ventricle under stress, such as anti-proBNP or troponin. The third concerns function and symptoms — how bad those symptoms are, or how limited their exercise capacity is. Merely having an echo revealing a thickened ventricle, plus perhaps a family history of HCM, probably isn't sufficient, at least right now, to consider starting treatment with the myosin inhibitor or any other therapy at this stage. Nearly all the therapies under investigation target patients who are symptomatic or functionally limited. That, then, is the kind of population I'd envision being enrolled in studies going forward.

Swapnil Malekar

analyst
#50

Swapnil here, filling in for Yasmeen. We have a few things to ask. To start, the label for mavacamten indicates a possible link to embryonic and fetal toxicity — is that an effect of the myosin inhibitor class as a whole, and what has been done with mavacamten to exclude that toxicity? Then, about the second Phase III study of mavacamten, though it isn't a head-to-head comparison involving mavacamten: are you suggesting it would lean toward patients with more severe disease, meaning those who receive therapy, and that this study would be roughly like the trial?

Robert Blum

executive
#51

Yes; I'd prefer to discuss aficamten and mavacamten instead. Regarding aficamten, if what you're asking is whether we might expect any reproductive toxicity — and I'll broaden that, since people have also asked us about any drug-drug interactions — perhaps I'll have Fady go into detail about what is known and what remains to be learned.

Fady Malik

executive
#52

Okay, so we carried out embryo-fetal toxicity research using aficamten, and those studies show no signs of aficamten causing direct harm to fetal development. If a medication is capable of making the mother — the maternal host — ill, as a cardiac myosin inhibitor might at larger doses, then it can definitely bring about fetal toxicity as a secondary consequence, yet we are not observing any direct fetal toxicity. Then, regarding your next question, about the kind of patients in SEQUOIA, we have skewed the entry criteria in the hope that this lets us enroll a population that leans somewhat more toward Class III, that leans somewhat more functional...

Diane Weiser

executive
#53

No, second trial — second Phase III.

Fady Malik

executive
#54

Regarding the second Phase III, which involves more severe cases — alright. Well, we aren't actually offering any remarks about that specific design, so providing an answer to what you asked isn't really possible for me. That said, the first one would definitely have been something I could address. So that's all I'll say on it.

Dane Leone

analyst
#55

This is Sean calling in for Dane. Since we've reached the conclusion of the call, we just have a few brief items. First, could you share your thoughts on the enrollment rate for SEQUOIA so far and how you think mavacamten's entry into the market might affect it? Then, secondly, a point of clarification regarding OpEx for the year. Your earlier guidance was upwards of $380 million, but it appears it might be trending lower. Just wanting some clarity on that.

Robert Blum

executive
#56

Sure; regarding the first item, SEQUOIA-HCM has only just begun. We're currently in the midst of arranging investigator meetings. The U.S. meeting was held not long ago, with others coming up. It's too early to say anything about enrollment yet, it's probably preferable to ask in the way we handle it regarding activations and initiations. And everything there appears fine, consistent with the plan. I don't know whether Fady, you or Stuart, would like to add anything to that.

Fady Malik

executive
#57

Yeah, I'd say it's premature to provide any clarity on the pace of enrollment, given that we're still at an early stage. What I can tell you is that investigators have shown a great deal of enthusiasm. And clearly, there's excitement around the fact that mavacamten is now available, though taking part in SEQUOIA gives patients a distinctive chance to help move the field forward and, in the end, to receive aficamten along with an open-label extension; I believe that will appeal to a lot of patients too. We should also point out that the trial will be conducted in parts of the world where mavacamten cannot be accessed. And in the end, my expectation is that enrollment will go quite well.

Robert Blum

executive
#58

At the time we said this study might complete enrollment in roughly twelve months, we fully expected mavacamten to secure U.S. approval, and that approval leaves our outlook on the enrollment pace unchanged. Then you asked about OpEx. I'll hand that one over to Ching, please.

Ching Jaw

executive
#59

Alright, that's correct. We said we expect cash burn for the year to fall between $365 million and $385 million. Naturally, Q1's figures came in below what you'd get by simply dividing that amount by 4, but that isn't how we actually approach OpEx planning for this year. As we explained before, we're scaling our commercial team and capabilities around hitting specific milestones across the year. So it follows that as we bring more people on board over the year, they'll add more expense in the back half than the front half; therefore, we do anticipate quarterly spending will rise compared with Q1's numbers.

Justin Kim

analyst
#60

Robert, perhaps I could add a bit more detail regarding a few of the inquiries that have already come up; however, since mava was recently approved and given its label, which appears to point toward the significance of ongoing development along with an expanded population, I'm simply wondering if it's sensible and perhaps even wise to anticipate additional trials, including ones past a second study in symptomatic HCM, considering that a variety of distinct populations might potentially derive benefit.

Robert Blum

executive
#61

Indeed; Justin, you attended the American College of Cardiology meetings. I noticed you were present. And as you observed, there is considerable excitement surrounding this novel mechanism, and it will probably produce a meaningful difference for these patients and the way they are treated; and this isn't merely something EXPLORER and SEQUOIA could account for. And you're correct, additional studies ought to exist, extending even past what we are considering with the second Phase III study, regardless of whether they occur before approval or after approval — more probably after approval, we hope, in any case, given our time lines. Yet we are already contemplating further studies that we perhaps ought to conduct involving aficamten, past the 2 Phase III studies we are discussing.

Justin Kim

analyst
#62

All right, that's great, thanks. One last thing, if I could, about the REMS program's requirement for an echo every 12 weeks. I'm just wondering whether you have any thoughts, or perhaps something more specific, on how the team expects that to shift more generally across myosin inhibitors, or perhaps specifically regarding SEQUOIA's design for afi, and how it could be altered over the longer term.

Robert Blum

executive
#63

You realize whatever we could tell you at this point amounts to speculation, given that a Phase III study is still underway; however, we have not been mandating the quantity of echoes that the mavacamten label presently envisions. Although reaching a starting dose for aficamten does require a couple of echoes, that can be accomplished in a few weeks rather than over a far lengthier stretch of time. As a result, we've experienced no dose discontinuations or interruptions at all. It's our expectation that, provided we keep developing aficamten the way we have been, frequent echo monitoring of that sort shouldn't be necessary, though that remains to be determined, the trial hasn't been run yet, and clinical evidence will be needed to demonstrate it. Fady, I'm not sure whether you'd like to add anything further.

Fady Malik

executive
#64

My view is simply that this will involve assessing whether ongoing oversight is required when aficamten is used as a long-term therapy, along with the open-label extension and whatever comes out of SEQUOIA; therefore, as Robert mentioned, the eventual label shape will be guided by the data.

Pete Stavropoulos

analyst
#65

Robert, Pete Stavropoulos here, filling in for Charles. Congratulations on everything you accomplished during the last quarter. One thing we'd like to ask is: what are the plans or expectations regarding an advisory committee for omecamtiv? What do you think the main discussion points would be, particularly when it comes to the disease burden among patients whose ejection fraction is, let's say, below 30%?

Robert Blum

executive
#66

As we told everyone before, we aren't expecting an adcom for omecamtiv tied to the NDA that was filed and is now under review; that matches what the FDA told us and what our public announcement showed. That doesn't mean it's impossible. Actually, it could happen, but we don't anticipate it, and nothing that has occurred since then gives us any reason to think it will. So our view remains that this application will go through review without an adcom, and our attention is on the PDUFA date later this year. Now, what was your second question?

Pete Stavropoulos

analyst
#67

And then for my second question, with the PDUFA date approaching in November, what do you believe needs to appear on the label for omecamtiv mecarbil in order for it to eventually be incorporated into a treatment guideline?

Robert Blum

executive
#68

That's a really good question. Treatment guidelines make room for foundational therapies, but also for other agents that might serve as add-on treatment. And perhaps I'll turn to Fady and Stuart to discuss what the guidelines set out and what that might indicate regarding where omecamtiv mecarbil could be placed within guidelines.

Fady Malik

executive
#69

Yeah. I believe, with the guidelines, definitely, foundational therapy that's specified involving four medication classes — beta blockers, a RAS inhibitor, an MRA plus an SGLT2 inhibitor — however not every patient is able to tolerate all 4 classes, and not every patient gets treated adequately; they might continue having symptoms. They might still be hospitalized. So the guidelines also lay out a number of add-on therapies, or therapies that could be supplemental to those in certain scenarios. And I think omecamtiv ought to be among those; and the data we've produced in GALACTIC and afterward in the analyses we've published show that sicker patients benefit to an even larger extent, to mavacamten. And presumably, the guidelines would reflect that.

Serge Belanger

analyst
#70

I have a few questions about the European partnership strategy. My understanding is that you restated your interest in finding a partner for omecamtiv while retaining the rights to aficamten. I just want confirmation that this is accurate; and then could you perhaps point out the timelines for omecamtiv's European approval and explain how you view that market opportunity compared with the one in the U.S.?

Robert Blum

executive
#71

Absolutely; I'll cover that and might also ask Andrew to speak to the second half of what you asked; our attention remains on securing a partner for omecamtiv mecarbil in Europe, which partly reflects the fact that we will be quite occupied with our targeted omecamtiv mecarbil work in the United States and with developing aficamten; and we recognize the reality of what success in Europe demands. Under Andrew's oversight, we have conducted exercises and planning to learn what companies in the peer group have done and what we consider feasible from our perspective; and before you can run, you have to walk. That being said, there is an attractive opportunity for omecamtiv mecarbil in Europe as there is in the United States, though it is clearly a smaller one given what we expect would be certain market access difficulties and pricing as well; with that, perhaps I'll hand things over to you, Andrew.

Andrew Callos

executive
#72

Right, Robert. Looking at it through the lens of potential, I'd say the total count for prevalence across Europe runs a touch greater — though not by a wide margin. It's close to what we see in the U.S., yet the price tag is clearly quite a bit cheaper. That's genuinely the main thing shaping the size of the chance when you look at Europe. Still, if you think about it the way we do for the U.S. — factoring in applicant plus omecamtiv and what an organization can achieve through synergies — the timing angle could make it more compelling. So, to give you a straight answer to what you asked, the opportunity is definitely smaller, and pricing is truly the reason behind that.

Robert Blum

executive
#73

We've made it quite plain that a major factor driving our determination to launch omecamtiv commercially in the United States is the expectation of concentrated customer segments that would let us establish a solid operation here, plus the synergies this gives us as we plan to bring aficamten to market. Europe presents the same situation, though at a different scale, and we must stay pragmatic regarding what's achievable within that same period. Consequently, our aim in partnering on omecamtiv mecarbil isn't to hand it off through an exclusive license; instead, we want a collaborator who could help us create an entry point for an aficamten business while also taking on a portion of the omecamtiv mecarbil obligations. That's how we're thinking about partnership.

Serge Belanger

analyst
#74

All right, and could omecamtiv possibly get approved in Europe during 2023? Or is there any time line we can point to right now?

Robert Blum

executive
#75

Yeah, we haven't actually addressed that directly so far. Clearly, it will depend on when an MAA gets filed and approval gets sought, and that hasn't occurred as of yet. Once again, our attention is on the U.S., though we are simultaneously working on those conversations with EMA and throughout Europe, and we'll share an update when we've got something firmer to discuss.

Serge Belanger

analyst
#76

All right. Let me fit in one final question. Would it be premature to discuss a possible schedule for when Cohort 4 data, from the REDWOOD trial, might be read out?

Robert Blum

executive
#77

Perhaps slightly. That's something we might be able to address during the following call. We'll wait and watch how enrollment progresses. It's an open-label study of 30 to 40 patients, as you're aware, and my expectation is that it will enroll at a good pace. So it may be a topic we can bring up on the next call.

Robert Blum

executive
#78

I appreciate it, operator, and I want to thank everyone who joined us on today's teleconference. Your ongoing backing and curiosity about Cytokinetics mean a great deal to us. Clearly, the opening quarter of this year proved extremely hectic yet highly fruitful. In addition, since we've gone over considerable territory during this call, my closing comments will be kept short. We're eager to bring you the open-label extension findings from REDWOOD-OLE before long, and to keep updating everyone regarding how things are progressing with omecamtiv mecarbil as well as aficamten, and, as we head toward the latter six months of this year, an initial interim analysis involving COURAGE-ALS. With those standing as the important milestones still ahead in the year, we're grateful for the time you've given us today. That being the case, we can now wrap up the call, please.

Operator

operator
#79

This concludes today's conference call. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.